SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:d5cffcd1-cdda-469a-bf65-c5342ab69a61"
 

Search: onr:"swepub:oai:lup.lub.lu.se:d5cffcd1-cdda-469a-bf65-c5342ab69a61" > Impact of the CYP4F...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Danese, E. (author)

Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

  • Article/chapterEnglish2012

Publisher, publication year, extent ...

  • 2012-11-07
  • Springer Science and Business Media LLC,2012

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:d5cffcd1-cdda-469a-bf65-c5342ab69a61
  • https://lup.lub.lu.se/record/3379377URI
  • https://doi.org/10.1038/clpt.2012.184DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I-2 = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Montagnana, M. (author)
  • Johnson, J. A. (author)
  • Rettie, A. E. (author)
  • Zambon, C. F. (author)
  • Lubitz, S. A. (author)
  • Suarez-Kurtz, G. (author)
  • Cavallari, L. H. (author)
  • Zhao, L. (author)
  • Huang, M. (author)
  • Nakamura, Y. (author)
  • Mushiroda, T. (author)
  • Kringen, M. K. (author)
  • Borgiani, P. (author)
  • Ciccacci, C. (author)
  • Au, N. T. (author)
  • Langaee, T. (author)
  • Siguret, V. (author)
  • Loriot, M. A. (author)
  • Sagreiya, H. (author)
  • Altman, R. B. (author)
  • Shahin, M. H. A. (author)
  • Scott, S. A. (author)
  • Khalifa, S. I. (author)
  • Chowbay, B. (author)
  • Suriapranata, I. M. (author)
  • Teichert, M. (author)
  • Stricker, B. H. (author)
  • Taljaard, M. (author)
  • Botton, M. R. (author)
  • Zhang, J. E. (author)
  • Pirmohamed, M. (author)
  • Zhang, X. (author)
  • Carlquist, J. F. (author)
  • Horne, B. D. (author)
  • Lee, M. T. M. (author)
  • Pengo, V. (author)
  • Guidi, G. C. (author)
  • Minuz, P. (author)
  • Fava, CristianoLund University,Lunds universitet,Kardiovaskulär forskning - hypertoni,Forskargrupper vid Lunds universitet,Cardiovascular Research - Hypertension,Lund University Research Groups(Swepub:lu)endo-cfa (author)
  • Kardiovaskulär forskning - hypertoniForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Clinical Pharmacology and Therapeutics: Springer Science and Business Media LLC92:6, s. 746-7561532-65350009-9236

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view